喉頭癌T2N0症例に対する化学放射線治療の検討

書誌事項

タイトル別名
  • Concurrent Chemoradiotherapy with Docetaxel for T2N0 Laryngeal Carcinoma
  • コウトウ ガン T2N0 ショウレイ ニ タイスル カガク ホウシャセン チリョウ ノ ケントウ

この論文をさがす

抄録

<p>A combination of docetaxel (DOC) therapy and radiotherapy was used to treat patients with T2N0 laryngeal carcinoma. Thirty-two patients with T2N0 laryngeal cancer received concurrent chemoradiotherapy (64.6–74 Gy) with weekly DOC (10 mg/m2). All the patients were male, and their average age was 66.3 years. All the patients achieved a complete response (CR). The overall survival rate, as determined using the Kaplan-Meier method, was 92.0%, and the disease-free survival rate was 92.2%. The local control rates were 88.0% for the glottis and 28.6% for the supraglottis and subglottis. Grade 3 or higher toxicities were seen in 4 patients. In conclusion, concurrent chemoradiotherapy with DOC is a feasible and effective treatment for glottic squamous cell carcinoma.</p>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ